Radical Openness for Adolescents Pilot (ROA)

Targeting the Transdiagnostic Mechanism of Performance Monitoring and Overcontrol in Adolescence: Adaptation and Feasibility

Heightened performance monitoring and overcontrol (HPM/OC) is characterized by inflexibility, a need for control, perfectionism, anxious apprehension and high error monitoring. HPM/OC is a cross-diagnostic (transdiagnostic) characteristic occurring across multiple forms of psychiatric illness that emerge in adolescence, including anorexia nervosa (AN), obsessive compulsive disorder (OCD) and social anxiety disorder. This study characterizes behavioral and neural HPM/OC in healthy adolescents and adolescents with disorders characterized by HPM/OC, including AN and related eating disorders and anxiety, depressive and obsessive compulsive disorders. We then examine feasibility of a novel treatment for HPM/OC in adolescents, examining recruitment feasibility, exploration of the mechanism of HPM/OC and examining whether treatment is able to target neural and behavioral HPM/OC.

Study Overview

Detailed Description

Eligible patient (n=30) and healthy (n=30) adolescents and young adults will attend a baseline session where they will undergo an ERP neural assessment and fill out questionnaires. 8 patient participants interested in participating in a 4 month free RO DBT therapy trial will participate in weekly individual and skills class sessions. At the end of this 4 months, they will complete a second follow-up session where they will undergo an event related potential (ERP) neural assessment and fill out questionnaires. 8 of the remaining 30 patient participants who do not want to complete the free therapy trial will have the option to return for a second follow-up session where they will undergo an ERP neural assessment and fill out questionnaires while undergoing treatment as usual (outside of therapy trial).

Study Type

Interventional

Enrollment (Actual)

61

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Missouri
      • Saint Louis, Missouri, United States, 63110
        • Washington University School of Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

Adolescents with HPM/OC: Female adolescents and young adults with AN and related eating disordered pathology and other disorders of HPM/OC. Inclusion criteria include ages 13-21, female gender, and must be characterized by elevated dimensional HPM/OC. Inclusion criteria also require a psychiatric disorder and/or impairment related to HPM/OC, including a diagnosis of AN, related eating disordered pathology related to AN that is characterized by HPM/OC (Eating disorder not otherwise specified; EDNOS; with high HPM/OC),and/or a diagnosis of a related disorder characterized by HPM/OC, namely obsessive compulsive disorder (OCD) or social anxiety disorder. Importantly, not only psychiatric illness, but psychiatric illness characterized by HPM/OC is required. Participants will not be excluded due to medication status. Other inclusion include: for adolescents younger than 17, the consent and participation of a legal caregiver. Other inclusion include if participating in therapy beyond baseline session: living in the St. Louis region (to attend sessions) and willingness to have RO DBT-A as only psychosocial treatment engaged in (medication treatment may continue).

Healthy adolescents: Female adolescents and young adults age 13-21 matched to patient sample on age and gender (all females). Inclusion criteria: no diagnosis of disorders of HPM/OC, including AN and related eating disordered pathology, OCD, or social anxiety disorder, ability to complete the EEG and baseline session, and scores below the clinical cut-off on a questionnaire, the Youth Self Report (YSR).

Exclusion Criteria:

Adolescents with HPM/OC: Exclusion criteria include: male gender, outside age range, significant developmental or cognitive delays, seizure or other major neurological disorder, severe head injury, inability to understand, speak and read English sufficiently (both adolescent and caregiver if under age 18).

Healthy adolescents: Exclusion criteria: male gender, outside age range, significant developmental or cognitive delays, seizure or other major neurological disorder, severe head injury, inability to understand, speak and read English sufficiently (both adolescent and caregiver if under age 18), or disorder of AN, OCD, Social Anxiety Disorder.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Treatment Group
Participants completed a baseline assessment, received 4 months of RO DBT therapy, then completed a follow-up assessment.
Radically Open Dialectical Behavior therapy (RO DBT) is a type of cognitive behavioral therapy developed by Dr. Thomas Lynch for disorders of emotional overcontrol. RO DBT is a treatment indicated for patients across multiple psychiatric disorders, including diagnoses of chronic depression, treatment resistant anxiety disorders, anorexia nervosa, autism spectrum disorders, and avoidant, paranoid, and obsessive-compulsive personality disorders.
No Intervention: No Treatment Group
Participants completed baseline assessment but did not receive treatment. A small subset also completed a follow-up assessment.
No Intervention: Healthy Controls
Participants completed baseline assessment but did not receive treatment.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in error-related negativity (ERN) amplitudes
Time Frame: Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
ERN data is obtained during electroencephalogram (EEG) sessions during which participants engage in several behavioral tasks. These tasks include Flankers (participant must quickly press an arrow key that corresponds to the center arrowhead depicted on the screen)
Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
Changes in scores on Overcontrol Youth Checklist (OCYC)
Time Frame: Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
The OCYC is a validated self-report checklist that assesses levels of hyper-performance monitoring and overcontrol. The youth is asked to respond yes/no to a variety of personality-based questions. A total score is generated, as well as a frustration/rigidity score and a social concern/perfectionism score.
Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
Changes in scores on Adolescent Over- and Under-control Trait Measure (OUT'M)
Time Frame: Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
The OUT'M is a validated self-report checklist that assesses levels of overcontrol as well as undercontrol. Youths are asked to rate themselves on a variety of personality traits using a scale from 0-6. Overcontrol and undercontrol scores are generated.
Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
Changes in Behavioral Reward Responding using the Temporal Experience of Pleasure Scale (TEPS), including the anticipatory and consummatory subscales
Time Frame: Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
The TEPS is an 18-item measure, rated from one ("very false for me") to six ("very true for me"; α = 0.89). Examples of items include "I look forward to a lot of things in my life" (anticipatory) and "I enjoy taking a deep breath of fresh air when I walk outside" (consummatory).
Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
Changes in Reward Positivity (RewP) amplitudes
Time Frame: Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
RewP data is obtained during electroencephalogram (EEG) sessions during which participants engage in a behavioral task of opening a door and receiving a small amount of money to win if they open the correct door, or lose a small amount of money if they do not open the 'correct' door. The RewP is measured by examining neural response to winning money subtracting out the neural response to losing money.
Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in disruptive eating symptomology using Eating Disorder Examination-Questionnaire (EDE-Q)
Time Frame: Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
The EDE-Q is a self-report measure of eating disorder pathology for the last 28 days. It is a 36-item, 7-point scale (Fairburn & Beglin, 1994). The resulting global score (α = 0.83), and four subscales, are comprised of item averages which, when over 4, indicate clinically significant eating pathology.
Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
Changes in anxious symptomology using Screen for Child Anxiety Related Disorders (SCARED)
Time Frame: Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
The SCARED is a 41-item scale (α = 0.90) rated from zero ("Not True or Hardly Ever True") to two ("Very True or Often True"). Summed total scores (α = 0.90) over 25 indicate clinically significant anxiety.
Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
Changes in functional impairment using Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQLES-Q)
Time Frame: Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
The PQLES-Q is a 15-item scale, with items rated from one ("Very Poor") to six ("Very Good") where the first 14 items are summed for a total score and the last item is a self-reported global measure (α = 0.93). Higher scores indicate higher satisfaction and enjoyment.
Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
Changes in social impairment using Social Connectedness Scale (SCS)
Time Frame: Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
The SCS is an 8-item measure, rated from one ("Agree") to six ("Disagree") and summed, with higher scores indicating more social connectedness (α = 0.91). An example item from the SCS is "I feel so distant from people".
Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
Changes in depressive symptomology using Child Depression Inventory (CDI)
Time Frame: Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])
The CDI is a 27-item scale rated from 0 to 2 and summed to create a total score. The suicidality question was omitted, yielding 26 questions. The T-score of the total score was used (α = 0.92).
Baseline (all groups), 4 months (treatment group, no treatment group [subset completing follow-up])

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 11, 2020

Primary Completion (Actual)

February 28, 2022

Study Completion (Actual)

February 28, 2022

Study Registration Dates

First Submitted

June 12, 2023

First Submitted That Met QC Criteria

June 12, 2023

First Posted (Actual)

June 22, 2023

Study Record Updates

Last Update Posted (Actual)

June 22, 2023

Last Update Submitted That Met QC Criteria

June 12, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anorexia Nervosa

Clinical Trials on Radically Open Dialectical Behavior Therapy (RO DBT)

Subscribe